2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Level 5 - mechanism / opinion, no new human data
Clinical practice guideline executive summary / expert panel consensus recommendations.
PubMed 30879339 · doi:10.1161/CIR.0000000000000677
What was done
The American College of Cardiology and American Heart Association Task Force summarized clinical practice guidelines for the primary prevention of atherosclerotic cardiovascular disease (ASCVD), heart failure, and atrial fibrillation. The executive summary synthesizes recommendations spanning lifestyle behaviors, team-based care, risk assessment tools, nutrition, exercise, diabetes management, smoking cessation, lipid control, and blood pressure targets.
What was found
The guideline outlines 10 primary recommendations: 1. Promote a healthy lifestyle throughout life. 2. Utilize team-based care and evaluate social determinants of health. 3. Conduct 10-year ASCVD risk calculation and clinician-patient discussions in adults aged 40–75 before starting pharmacological therapy, considering risk-enhancing factors and coronary artery calcium scoring. 4. Recommend a diet rich in vegetables, fruits, nuts, whole grains, lean protein, and fish, while minimizing trans fats, processed meats, refined carbohydrates, and sweetened drinks, with caloric restriction for overweight/obese adults. 5. Prescribe at least 150 minutes per week of moderate-intensity or 75 minutes per week of vigorous-intensity physical activity. 6. For type 2 diabetes, emphasize lifestyle modifications, metformin as first-line pharmacotherapy, followed by SGLT2 inhibitors or GLP-1 receptor agonists if indicated. 7. Screen for tobacco use at every visit and provide cessation support. 8. Restrict routine aspirin use for primary ASCVD prevention due to lack of net benefit. 9. Initiate first-line statin therapy for LDL-C ≥190 mg/dL, adults aged 40–75 with diabetes, or those with sufficient assessed ASCVD risk. 10. Implement nonpharmacological BP interventions, aiming for a pharmacological target of <130/80 mm Hg when medication is required. No effect sizes, relative risks, or statistical test values were provided in the abstract.
Why it matters
This guideline established a modern consensus for cardiovascular prevention, notably standardizing the shift away from routine aspirin use in primary prevention and emphasizing comprehensive lifestyle modification alongside objective 10-year risk stratification.
Limits
The abstract provides high-level guideline recommendations without reporting underlying study methodologies, sample sizes, search strategies, or quantitative effect sizes (such as odds ratios or absolute risk reductions). Specific thresholds and risk discussions rely partly on clinical judgment.
Cited by
- supports Cardiovascular and lipid guidelines establish an LDL cholesterol level of 190 mg/dL or greater as a threshold mandating clinical intervention and statin therapy, often driven by underlying genetic conditions such as LDL receptor abnormalities.